• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    LivePerson And 2 Other Stocks Under $2 Insiders Are Buying

    3/19/24 7:55:14 AM ET
    $AWRE
    $LPSN
    $RNAC
    Computer Software: Prepackaged Software
    Technology
    Computer Software: Prepackaged Software
    Technology
    Get the next $AWRE alert in real time by email

    The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

    Cartesian Therapeutics

    • The Trade: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Timothy A Springer acquired a total of 1,185,872 shares an average price of $0.56. To acquire these shares, it cost around $666,222.
    • What’s Happening: On March 18, HC Wainwright & Co. analyst Mitchell Kapoor reiterated Cartesian Therapeutics with a Buy and maintained a $2 price target.
    • What Cartesian Therapeutics Does: Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company.

    Aware

    • The Trade: Aware, Inc. (NASDAQ:AWRE) CEO and President Robert A Eckel acquired a total of 13,735 shares at at an average price of $1.67. To acquire these shares, it cost around $22,881.
    • What’s Happening: On March 12, Aware reported a year-over-year decrease in fourth-quarter EPS results..
    • What Aware Does: Aware Inc is a provider of software and services to the biometrics industry. The company's software products are used in government and commercial biometrics systems to identify or authenticate people.

    Check This Out: Investor Optimism Decreases Ahead Of Fed Meeting; S&P Snaps 3-Session Losing Streak

    LivePerson

    • The Trade: LivePerson, Inc. (NASDAQ:LPSN) Director Vanessa Pegueros acquired a total of 5,000 shares at an average price of $1.02. The insider spent around $5,100 to buy those shares.
    • What’s Happening: On Feb. 28, LivePerson reported mixed fourth-quarter financial results and issued 2024 total revenue guidance below estimates.
    • What LivePerson Does: LivePerson Inc is the enterprise leader in digital customer conversation.

     

    Don’t forget to check out our premarket coverage here

     

    Get the next $AWRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AWRE
    $LPSN
    $RNAC

    CompanyDatePrice TargetRatingAnalyst
    Cartesian Therapeutics Inc.
    $RNAC
    7/9/2025$38.00Outperform
    Wedbush
    Cartesian Therapeutics Inc.
    $RNAC
    12/19/2024$42.00Buy
    BTIG Research
    LivePerson Inc.
    $LPSN
    11/8/2024$1.00Buy → Hold
    Craig Hallum
    Cartesian Therapeutics Inc.
    $RNAC
    8/6/2024Buy
    TD Cowen
    Cartesian Therapeutics Inc.
    $RNAC
    7/2/2024Outperform → Perform
    Oppenheimer
    Cartesian Therapeutics Inc.
    $RNAC
    6/4/2024$50.00Outperform
    Oppenheimer
    Cartesian Therapeutics Inc.
    $RNAC
    5/24/2024$40.00Buy
    Mizuho
    Cartesian Therapeutics Inc.
    $RNAC
    4/23/2024$2.00 → $54.00Buy
    H.C. Wainwright
    More analyst ratings

    $AWRE
    $LPSN
    $RNAC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LivePerson Named a Leader in the Aragon Research Globe™ for Agent Platforms 2026

    The conversational AI and AI agent evaluation platform was recognized alongside other major platformsNEW YORK, Feb. 27, 2026 /PRNewswire/ -- LivePerson (NASDAQ:LPSN), a leading provider of predictable conversational AI, today announced Aragon Research, Inc. has positioned LivePerson in the Leader section of "The Aragon Research Globe™ for Agent Platforms, 2026," a report that evaluates 21 major providers of AI agent platforms and examines the shift from chatbot to sophisticated AI agent systems. "We believe our positioning as a Leader in the Aragon Research Globe confirms our co

    2/27/26 8:00:00 AM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    Cartesian Therapeutics to Participate in Upcoming Investor Conferences

    FREDERICK, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in March and April: A presentation at the 46th Annual TD Cowen Health Care Conference at 11:50 a.m. ET Monday, March 2, 2026A fireside chat at Leerink's Global Healthcare Conference at 10:00 a.m. ET on Monday, March 9, 2026A fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 a.m. ET on Monday, April 13, 2026 Live webcasts of the fireside chats and presentation are expect

    2/23/26 7:00:00 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aware Sets Fourth Quarter and Full Year 2025 Webcast for Wednesday, March 4, 2026, at 5:00 p.m. Eastern Time

    BURLINGTON, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aware, Inc. (NASDAQ:AWRE), global leader in biometric identity and authentication solutions, will hold a webcast on Wednesday, March 4, 2026, at 5:00 p.m. Eastern time to discuss its financial results for the fourth quarter and fiscal year ended December 31, 2025. Financial results will be issued in a press release before the call. Aware management will host the webcast presentation, followed by a question-and-answer session. Date: Wednesday, March 4, 2026Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)Webcast: Register Here Interested parties may submit questions in advance of the webcast by emailing [email protected].

    2/18/26 8:31:00 AM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barabe Timothy C bought $205,797 worth of shares (30,000 units at $6.86), increasing direct ownership by 123% to 54,366 units (SEC Form 4)

    4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

    12/8/25 4:07:12 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Amlani Ajay K bought $34,608 worth of shares (15,489 units at $2.23), increasing direct ownership by 2% to 838,041 units (SEC Form 4)

    4 - AWARE INC /MA/ (0001015739) (Issuer)

    11/5/25 5:35:40 PM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    President & CEO Amlani Ajay K bought $38,824 worth of shares (17,679 units at $2.20), increasing direct ownership by 2% to 822,552 units (SEC Form 4)

    4 - AWARE INC /MA/ (0001015739) (Issuer)

    9/2/25 5:53:16 PM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Johnstone Brent P

    4 - AWARE INC /MA/ (0001015739) (Issuer)

    2/25/26 6:09:46 PM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Evee Gary

    4 - AWARE INC /MA/ (0001015739) (Issuer)

    2/25/26 6:08:58 PM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Director Connolly Brian D

    4 - AWARE INC /MA/ (0001015739) (Issuer)

    2/25/26 6:08:00 PM ET
    $AWRE
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.

    SCHEDULE 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    2/5/26 1:20:38 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: LivePerson Inc. filed SEC Form 8-K: Leadership Update

    8-K/A - LIVEPERSON INC (0001102993) (Filer)

    1/28/26 4:42:00 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    Cartesian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

    1/9/26 8:06:08 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AWRE
    $LPSN
    $RNAC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush initiated coverage on Cartesian Therapeutics with a new price target

    Wedbush initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $38.00

    7/9/25 8:26:19 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Cartesian Therapeutics with a new price target

    BTIG Research initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $42.00

    12/19/24 8:25:53 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LivePerson downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded LivePerson from Buy to Hold and set a new price target of $1.00

    11/8/24 8:18:21 AM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    Financials

    Live finance-specific insights

    View All

    LivePerson Announces Third Quarter 2025 Financial Results

    -- Total Revenue of $60.2 million, above the high end of our guidance range -- -- Adjusted EBITDA above the high end of our guidance range  -- NEW YORK, Nov. 10, 2025 /PRNewswire/ -- LivePerson, Inc. (NASDAQ:LPSN) ("LivePerson" the "Company", "we" or "us"), a leading provider of predictable conversational AI and digital transformation, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights Total revenue was $60.2 million for the third quarter of 2025, a decrease of 19.0% as compared to the same period last year, driven primar

    11/10/25 4:30:00 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    LivePerson to Announce Third Quarter 2025 Financial Results on November 10, 2025

    NEW YORK, Oct. 28, 2025 /PRNewswire/ -- LivePerson, Inc. (NASDAQ:LPSN), a leading provider of trusted enterprise conversational AI and outcome-driven digital transformation, today announced the planned release of its second quarter financial results after the market close on Monday, November 10, 2025. CEO John Sabino and CFO & COO John Collins will host a conference call later that day, at 5:00 p.m. Eastern Time. The conference call will be simulcast live and can be accessed by logging onto the investor relations section of the Company's web site at Investor Relations | LivePe

    10/28/25 8:30:00 AM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    LivePerson Announces Second Quarter 2025 Financial Results

    -- Total Revenue of $59.6 million, at the high-end of our guidance range -- -- Adjusted EBITDA above the high-end of our guidance range  -- NEW YORK, Aug. 11, 2025 /PRNewswire/ -- LivePerson, Inc. (NASDAQ:LPSN) ("LivePerson" the "Company", "we" or "us"), a leading provider of trusted enterprise conversational AI and outcome-driven digital transformation, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights Total revenue was $59.6 million for the second quarter of 2025, a decrease of 25.4% as compared to the same period last ye

    8/11/25 4:30:00 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

    SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

    11/18/24 9:44:37 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by LivePerson Inc.

    SC 13G/A - LIVEPERSON INC (0001102993) (Subject)

    11/14/24 5:21:06 PM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SC 13G/A filed by LivePerson Inc.

    SC 13G/A - LIVEPERSON INC (0001102993) (Subject)

    11/14/24 10:52:06 AM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology

    $AWRE
    $LPSN
    $RNAC
    Leadership Updates

    Live Leadership Updates

    View All

    Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

    Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinical trial offering potential opportunity for a single pivotal trial expected to commence in 1H26 Phase 1/2 pediatric trial of Descartes-08 in juvenile dermatomyositis initiated Cash resources expected to support planned operations, including completion of planned Phase 3 trial for Descartes-08 for myasthenia gravis, into mid-2027 FREDERICK, Md., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune dise

    1/9/26 8:04:14 AM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

    FREDERICK, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the appointment of Adrian Bot, M.D., Ph.D., to the Company's Board of Directors. Dr. Bot is a biopharma executive with three decades of experience in research and development (R&D) with a focus on immune, cell, gene therapy and nanomedicines. He will serve as a member of the Science and Technology Committee of the Board. "Dr. Bot brings a unique perspective shaped by pioneering work in first-in-class CAR T cell therapies, including the recent historic acquisition of Capstan's no

    12/18/25 4:05:00 PM ET
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tripp Lane Joins LivePerson Board of Directors

    NEW YORK, Nov. 17, 2025 /PRNewswire/ -- LivePerson (NASDAQ:LPSN), a leading provider of predictable conversational AI and digital transformation, today announced that Nathan "Tripp" Lane has been appointed to its Board of Directors. "We are excited to welcome Tripp to the LivePerson Board," said Jim Miller, Board Chair. "Tripp's extensive experience guiding technology companies on strategy, operational effectiveness, and business transformation as a board director, operator, and investment advisor provides a unique perspective that will be an asset as we focus on execution and

    11/17/25 8:30:00 AM ET
    $LPSN
    Computer Software: Prepackaged Software
    Technology